Related Experiment Video
Updated: Jul 6, 2026
08:16
Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture
Published on: February 11, 2019
Human pancreatic duct epithelial cell model for KRAS transformation
Nikolina Radulovich1, Jia-ying Qian, Ming-Sound Tsao
1Division of Applied Molecular Oncology, Ontario Cancer Institute, University Health Network, Ontario, Canada.
Methods in Enzymology
|April 1, 2008
Summary
KRAS mutations are common in pancreatic cancer. This study developed a new model using human pancreatic duct cells to investigate how KRAS mutations drive cancer development, revealing insights into early carcinogenesis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- KRAS gene mutations are early events in pancreatic duct cell carcinogenesis, found in up to 90% of pancreatic ductal adenocarcinoma.
- The precise functional role of KRAS mutations in the malignant transformation of pancreatic duct epithelial cells remains unclear.
Purpose of the Study:
- To establish an in vitro model for studying KRAS-driven pancreatic duct cell transformation.
- To investigate the molecular and cellular mechanisms underlying human pancreatic duct cell carcinogenesis initiated by KRAS mutations.
Main Methods:
- Development of an in vitro model using near-normal HPV-16E6E7-immortalized human pancreatic ductal epithelial (HPDE-E6E7) cells.
- Retroviral transduction to express mutant KRAS(G12V) in HPDE cells.
- In vivo assessment of tumorigenic potential in immune-deficient scid mice.
Main Results:
- Expression of mutant KRAS(G12V) induced weak tumorigenic transformation in HPDE cells.
- Tumors formed in 50% of immune-deficient scid mice implanted with KRAS-transformed cells.
- The model successfully demonstrated KRAS-mediated transformation in a human pancreatic cell line.
Conclusions:
- The developed in vitro model serves as a valuable tool for dissecting the molecular mechanisms of pancreatic carcinogenesis.
- This research provides a foundation for further investigation into the role of KRAS mutations in pancreatic cancer development.
